Engineered Nucleic Acids Encoding a Modified Erythropoietin and Their Expression
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 9 of these applications claim priority to application 61/470,451, filed Mar 31, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,710,200 | Engineered Nucleic Acids Encoding a Modified Erythropoietin and Their Expression In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 9,533,047 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 9,950,068 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 10,898,574 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 11,911,474 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 12,364,763 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 12,409,226 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 12,419,957 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| US 12,502,431 | Delivery and Formulation of Engineered Nucleic Acids In force · High confidence | ModernaTX, Inc. | In force | High confidence | ||
| Application 13/897,362 | Modified Polynucleotides for the Production of Factor IX Abandoned Abandoned Aug 24, 2015 | ModernaTX, Inc. | Abandoned | Abandoned Aug 24, 2015 | ||
| 1 more patent in this group · Pro | ||||||
10 of 11 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 11.
9 of these are in force and held by ModernaTX, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.